Hypertrophic cardiomyopathy (HCM) is generally an inherited global heart disease in which only a fraction of those with the condition are clinically diagnosed. The recently published HCM guidelines include major changes focusing on medical therapy, increased emphasis exercise testing, management of sudden death risk, and screening for atrial fibrillation. 

In this interview, Drs. Matthew Martinez and Himabindu Vidula reinforce the importance of these updates for general cardiologists, which aid in identifying HCM patients early and establishing appropriate management plans.  

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

Advanced lipid testing holds significant potential in cardiovascular care by enhancing risk prediction beyond standard lipid panels. For patients, this means more tailored treatment and better outcomes by addressing residual risk not captured by traditional LDL-C assessments​.  

 In this interview, Drs. Laxmi Mehta and Michael Shapiro discuss the role and importance of advanced lipid testing.  

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

he SUMMIT trial compared the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results from the trial concluded that treatment of obesity reduces major heart failure events in addition to improving health status and exercise tolerance. 

In this interview, Drs. Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Nearly one-half of US counties have no practicing cardiologists. These counties with limited access to cardiovascular care tend to be more rural and socioeconomically disadvantaged, with a greater burden of cardiovascular disease, highlighting deep geographic disparity in access to cardiovascular care in the US. 

In this interview, Drs. Bailey and Kim discuss “Geographic Disparities in Access to Cardiologists in the United States.” 

 Related References: 

1. Cross SH, Mehra MR, Bhatt DL, et al. Rural-urban differences in cardiovascular mortality in the US, 1999-2017. JAMA 2020;323:1852–54.  

1. Loccoh EC, Nguyen A, Kim G, Warraich HJ. Geospatial analysis of access to health care and internet services in the US. JAMA Netw Open 2022;5:e2243792. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Dhanunjaya Lakkireddy, MD, MBA, FACC, and Alison L. Bailey, MD FACC, discuss the Top Electrophysiology (EP) Takeaways from 2024. Dr. Lakkireddy discusses climate change, high school mandated education on cardiopulmonary resuscitation, important trials impacting atrial fibrillation including PROMPT-AF and ARREST-AF, and more.  

1. Sang C, Liu Q, Lai Y, et al. Pulmonary vein isolation with optimized linear ablation vs pulmonary vein isolation alone for persistent AF: the PROMPT-AF randomized clinical trial. JAMA 2024;Nov 18:[ePub ahead of print].  

1. Wood S. Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF 

(tctMD website). 2024. Available at https://www.tctmd.com/news/lifestyle-and-risk-factors-matter-af-burden-metformin-may-not-trim-af. Accessed 12/17/24. 

1. Verma S, Butler J, Borlaug BA, et al.; on behalf of STEP-HFpEF and STEP-HFpEF DM Investigators. Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program. J Am Coll Cardiol 2024;84:1603-14. 

1. Sapp JL, Tang AS, Parkash R, et al., for the VANISH2 Study Team. Catheter ablation or antiarrhythmic drugs for ventricular tachycardia. N Engl J Med 2024;Nov 16:[ePub ahead of print]. 

1. Katapadi A, Bawa D, Garg J, et al. Are high school cardiopulmonary resuscitation education mandates working? Insights from a high school survey on CPR knowledge, attitudes, and readiness. Heart Rhythm 2024;Sep 28:[ePub ahead of print]. 

1. Yang CH, Ng CJ, Huang HL, et al. Intraosseous and intravenous epinephrine administration routes in out-of-hospital cardiac arrest: survival and neurologic outcomes. J Am Heart Assoc 2024;13:e036739.  

1. Prioritizing Health | Weathering Change: The Importance of Talking to Patients About Environmental Risks to Heart Health (Cardiology Magazine). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/04/01/00/42/Prioritizing-Health-Weathering-Change-The-Importance-of-Talking-to-Patients-About-Environmental-Risks-to-Heart-Health. Accessed 12/17/24. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC’s proposal for a new Board of Cardiovascular Medicine, and more.  

1. Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75. 

1. Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare beneficiaries. JACC Adv 2024;3:101275. 

1. FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients With ATTR-CM (ACC.org). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/11/26/15/02/fda-update-acoramidis-approved-to-reduce-cv-death-hospitalization-in-patients-with-attr-cm. Accessed 12/10/24. 

1. Gillmore JD, Judge DP, Cappelli F, et al., on behalf of the ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.  

1. Board of Cardiovascular Medicine (ACC.org). 2024. https://cvboard.org/. Accessed 12/10/24. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Clyde W. Yancy, MD, MACC, and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2024. Dr. Yancy discusses the FINEARTS-HF trial, the PREVENT calculator, the multisociety Heart Failure Guidelines, and more. 

1. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 2023;148:1982-2004. 

1. Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:435-47.  

1. Solomon SD, McMurray JJV, Vaduganathan M, et al; on behalf of the FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475-85. 

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:e263–e421. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2024. Dr. Bairey Merz discusses the SELECT and SUMMIT trials, the impact of cardiac interventions on the carbon footprint, and more.  

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; on behalf of the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. 

1. Packer M, Zile MR, Kramer CM, et al; on behalf of the SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2024;Nov 16:[ePub ahead of print]. 

1. TOPSPIN  ̶̶  Treatment Optimization for Blood Pressure With Single-Pill Combinations in India. Presented by Dr. Dorairaj Prabhakaran at the American Heart Association Scientific Sessions, Chicago, IL, November 17, 2024.   

1. Sagheer U, Al-Kindi S, Abohashem S, et al. Environmental pollution and cardiovascular disease: part 1 of 2: air pollution. JACC Adv 2023;3:100805. 

1. Sagheer U, Al-Kindi S, Abohashem S, et al. Environmental pollution and cardiovascular disease: part 2 of 2: soil, water, and other forms of pollution. JACC Adv 2024;3:100815. 

1. Bawa D, Ahmed A, Darden D, et al. Impact of remote cardiac monitoring on greenhouse gas emissions: Global Cardiovascular Carbon Footprint Project. JACC Adv 2023;2:100286. 

1. Marfella R, Prattichizzo F, Sardu C, et al. Microplastics and nanoplastics in atheromas and cardiovascular Events. N Engl J Med 2024;390:900-10. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Deepak L Bhatt, MD, MPH, MBA, FACC, and Alison L. Bailey, MD FACC, discuss the Top Interventional Takeaways from 2024. Dr. Bhatt discusses the CLEAR SYNERGY, DanGer Shock, EARLY TAVR trials and more. 

 Jolly SS, d’Entremont MA, Lee SF, et al., for the CLEAR Investigators. Colchicine in Acute Myocardial Infarction. N Engl J Med 2024;Nov 17:[Epub ahead of print]. 

1. Møller JE, Engstrøm T, Jensen LO, et al., on behalf of the DanGer Shock Investigators. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med 2024;390:1382-93. 

1. Généreux P, Schwartz A, Oldemeyer JB, et al., for the EARLY TAVR Trial Investigators. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med 2024;Oct 28:[Epub ahead of print]. 

1. Erriquez A, Campo G, Guiducci V, et al. QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial. JACC Cardiovasc Interv 2024;17:1425-36. 

1. Généreux P, Banovic M, Kang K-H, et al. Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: a systematic review and meta-analysis. J Am Coll Cardiol 2024;Nov 26:[ePub ahead of print]. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Thomas H. Marwick, MD, PhD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Takeaways from 2024 in Cardiovascular (CV) Imaging. Dr. Marwick discusses the SCOT-HEART trial, patient-echo reports augmented by AI, tricuspid valve regurgitation, and more. 

1. Dahl JS, Julakanti R, Ali M, Scott CS, Padang R, Pellikka PA. Cardiac damage in early aortic stenosis: is the valve to blame? JACC Cardiovasc Imaging 2024;17:1031-1040.  

1. Kolossvary M, Lin A, Kwiecinski J, et al. Coronary plaque radiomic phenotypes predict fatal or nonfatal myocardial infarction: analysis of the SCOT-HEART trial. JACC Cardiovasc Imaging 2024;Oct 30:[ePub ahead of print].  

1. Naser JA, Harada T, Tada A, et al. Prevalence, incidence, and outcomes of diastolic dysfunction in isolated tricuspid regurgitation: perhaps not really "isolated"? JACC Cardiovasc Imaging 2024;Jul 24:[ePub ahead of print].  

1. Spartera M, Stracquadanio A, Pessoa-Amorim G et al. Reduced left atrial rotational flow is independently associated with embolic brain infarcts. JACC Cardiovasc Imaging 2023;16:1149-59. 

1. Martin JA, Hill T, Saric M, et al. Evaluating patient-oriented echocardiogram reports augmented by artificial intelligence. JACC Cardiovasc Imaging 2024;17:1381-83. 

1. Sayed A, Al-Mallah M. Geographic proximity to cardiac positron emission tomography facilities across the United States. JACC Cardiovasc Imaging 2024;Aug 18:[ePub ahead of print].  

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL